Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

WCC Introduces New Service for Oncology Imaging Studies Involving irRC

Published: Friday, August 16, 2013
Last Updated: Friday, August 16, 2013
Bookmark and Share
New service enables combination tumor assessments using both RECIST and irRC.

WorldCare Clinical, LLC (WCC) has announced a new service that enables efficient capture and analysis of both standard tumor assessment, such as RECIST (Response Evaluation Criteria in Solid Tumors), and the newer immune-related response criteria (irRC) simultaneously.

Developed in collaboration with leading academic researchers, WCC’s method has been validated and is being used to evaluate new immune-related treatments.

WCC developed its combination case report form (CRF) to facilitate concurrent tumor assessments using both methods. The new service was designed for sponsors developing immunotherapeutic agents who want to analyze performance using irRC, but also want to capture RECIST responses until the newer irRC becomes more established.

“Employing a combined approach to tumor assessment allows for time savings when performing the imaging interpretation, resulting in a significant cost savings to the sponsor,” said Richard Walovitch, Ph.D., president of WorldCare Clinical.

Walovitch continued, “Using our combination CRF, we’re able to programmatically calculate the response using the criteria of both methods.”

WCC Director of Software Engineering Patrick Chokron will present on the benefits of combining both tumor assessment approaches at the upcoming Immunomodulatory Therapeutic Antibodies for Cancer conference, August 13-15, 2013 in Boston.

Chokron’s presentation, “Image Assessment in Immunotherapeutic Trials: Combining irRC and RECIST 1.1,” will take place at the Hilton Boston Back Bay Hotel on Thursday, August 15, 2013 at 12:00 p.m.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

WorldCare Clinical Promotes Richard Walovitch, Ph.D., to President
WorldCare Clinical, LLC (WCC), an imaging CRO for clinical trials in the pharmaceutical, biotechnology and medical device industries, today announced that it has promoted Richard Walovitch, Ph.D., formerly chief medical officer, to president.
Thursday, November 25, 2010
Scientific News
Therapy Halts Progression of Lou Gehrig’s Disease
Researchers at Oregon State University announced today that they have essentially stopped the progression of amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease, for nearly two years in one type of mouse model used to study the disease – allowing the mice to approach their normal lifespan.
New Mechanism of Antitumor Action Identified
A team of UAB researchers and collaborators from the Catalan biotech company Ability Pharmaceuticals (UAB Research Park), have described a new mechanism of anti-tumour action, identified during the study and development of the new drug ABTL0812.
Experimental Combination Surprises with Anti-HIV Effectiveness
A compound developed to protect the nervous system from HIV surprised researchers by augmenting the effectiveness of an investigational antiretroviral drug beyond anything expected.
UTSW Researchers Identifies How Drugs Alter Pancreatic Cancer Cells
The findings were published in Cell Reports.
Researchers Identify Process that Causes Chronic Neonatal Lung Disease
Study determines how the NLRP3 inflammasome activates the protein Interleukin 1 beta.
Dengue Vaccine Enters Phase 3 Trial
Investigational vaccine to prevent ‘breakbone fever’ developed at NIH.
Trying to Conceive Soon After a Pregnancy Loss May Increase Chances of Live Birth
NIH study finds no reason for delaying pregnancy attempts after a loss without complications.
BRCA1 Deficiency Increases the Sensitivity of Ovarian Cancer Cells to Auranofin
An anti-rheumatic drug could improve the prognosis for ovarian cancer patients exhibiting a deficiency of the DNA repair protein BRCA1, a study suggests.
Shingles Vaccine Helps Protect Older Patients with End-stage Renal Disease
Kaiser Permanente study advances knowledge about safety and effectiveness of vaccine commonly given to older adults.
AMRI Acquires Whitehouse Laboratories
Strategically extends AMRI's analytical offerings in rapidly expanding area of outsourcing services.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!